Developmental cholinotoxicants: Nicotine and chlorpyrifos

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 1, 1999, Pages 71-80

  Slotkin, Theodore A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenylyl cyclase; Apoptosis; Chlorpyrifos; Cholinergic neurotoxicants; DNA synthesis; Nicotine

Indexed keywords

ADENYLATE CYCLASE; CHLORPYRIFOS; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BRAIN DEVELOPMENT; CELL DIVISION; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DNA SYNTHESIS; FETUS; GENE EXPRESSION; NERVE CELL DIFFERENTIATION; NEUROTOXICITY; NONHUMAN; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALIA;

EID: 0032908419     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s171     Document Type: Review

References (106)

1. Buznikov GA, Chudakova IV, Zvedina ND. The role of neurohumors in early embryogenesis. 1 : Serotonin content of developing embryos of sea urchin and loach. J Embryol Exp Morphol 12:563-573 (1964).
2. Buznikov GA, Kost AN, Berdysheva LV. The role of neurohumours in early embryogenesis. 3: Pharmacological analysis of the role of neurohumours in cleavage divisions. J Embryol Exp Morphol 23:549-569 (1970).
3. Lauder JM. Roles for neurotransmitters in development: possible interaction with drugs during the fetal and neonatal periods. In: Prevention of Physical and Mental Congenital Defects (Marois M, ed). New York:Alan R. Liss, 1985;375-380.
4. Whitaker-Azmitia PM. Role of serotonin and other neurotransmitter receptors in brain development: basis for developmental pharmacology. Pharmacol Rev 43:553-561 (1991).
5. Yanai J. Neurobehavioral Teratology. Amsterdam:Elsevier, 1984.
6. Hohmann CF, Wilson L. Coyle JT. Efferent and afferent connections of mouse sensory-motor cortex following cholinergic deafferentation at birth. Cereb Cortex 1:1158-172 (1991).
7. Bachman ES, Berger-Sweeney J, Coyle JT, Hohmann CF. Developmental regulation of adult cortical morphology and behavior: an animal model for mental retardation, Int J Dev Neurosci 12:239-253 (1994).
8. Hohmann CF, Brooks AR, Coyle JT. Neonatal lesions of the basal forebrain cholinergic neurons result in abnormal cortical development. Dev Brain Res 42:253-264 (1988).
9. Navarro HA, Seidler FJ, Eylers JP, Baker FE, Dobbins SS, Lappi SE, Slotkin TA. Effects of prenatal nicotine exposure on development of central and peripheral cholinergic neurotransmitter systems. Evidence for cholinergic trophic influences in developing brain. J Pharmacol Exp Ther 251:894-900 (1989).
10. McFarland BJ, Seidler FJ, Slotkin TA. Inhibition of DNA synthesis in neonatal rat brain regions caused by acute nicotine administration. Dev Brain Res 58:223-229 (1991).
11. Bell JM, Lundberg PK. Effects of a commercial soy lecithin preparation on development of sensorimotor behavior and brain biochemistry in the rat. Dev Psychobiol 18:59-66 (1985).
12. Bell JM, Whitmore WL, Barnes G, Seidler FJ, Slotkin TA. Perinatal dietary exposure to soy lecithin: altered sensitivity to central cholinergic stimulation, Int J Dev Neurosci 4:497-501 (1986).
13. Bardy AH, Seppala T, Lillsunde P, Kataja JM, Koskela P, Pikkarainen J, Hiilesmaa VK. Objectively measured tobacco exposure during pregnancy: neonatal effects and relation to maternal smoking. Br J Obstet Gynaecol 100:721-726 (1993).
14. DiFranza JR, Lew RA. Effect of maternal cigarette smoking on pregnancy complications and Sudden Infant Death Syndrome. J Fam Pract 40:385-394 (1995).
15. Butler,NR, Goldstein H. Smoking in pregnancy and subsequent child development. Br Med J 4:573-574 (1973).
16. Naeye RL. Effects of maternal cigarette smoking on the fetus and placenta. Br J Obstet Gynaecol 85:732-737 (1978).
17. Naeye RL, Peters EC. Mental development of children whose mothers smoked during pregnancy. Obstet Gynecol 64:601-607 (1984).
18. Naeye RL. Cognitive and behavioral abnormalities in children whose mothers smoked cigarettes during pregnancy. J Dev Behav Pediatr 13:425-8 (1992).
19. Dunn HG, McBurney AK. Cigarette smoking and the fetus and child. Pediatrics 60:772 (1977).
20. Bell GL, Lau K. Perinatal and neonatal issues of substance abuse. Pediatr Clin North Am 42:261-281 (1995).
21. Martin JC, Becker RF. The effects of nicotine administration in utero upon activity in the rat. Psychon Sci 19:59-60 (1970).
22. Martin JC, Becker RF. The effects of maternal nicotine absorption or hypoxic episodes upon appetitive behavior of rat offspring. Dev Psychobiol 4:133-147 (1971).
23. Nasrat HA, Al-Hachim GM, Mahmood FA. Perinatal effects of nicotine. Biol Neonate 49:8-14 (1986).
24. Slotkin TA, Greer N, Faust J, Cho H, Seidler FJ. Effects of maternal nicotine injections on brain development in the rat: ornithine decarboxylase activity, nucleic acids and proteins in discrete brain regions. Brain Res Bull 17:41-50 (1986).
25. Slotkin TA, Cho H, Whitmore WL. Effects of prenatal nicotine exposure on neuronal development: selective actions on central and peripheral catecholaminergic pathways. Brain Res Bull 18:601-611 (1987).
26. 3H]nicotine binding sites in brain regions of rats exposed to nicotine prenatally via maternal injections or infusions. J Pharmacol Exp Ther 242:232-237 (1987).
27. Slotkin TA, Cowdery TS, Orband L, Pachman S, Whitmore WL. Effects of neonatal hypoxia on brain development in the rat: immediate and long-term biochemical alterations in discrete regions. Brain Res 374:63-74 (1986).
28. Seidler FJ, Slotkin TA. Effects of acute hypoxia on neonatal rat brain: regionally selective, long-term alterations in catecholamine levels and turnover. Brain Res Bull 24:157-161 (1990).
29. Carlos RQ, Seidler FJ, Lappi SE, Slotkin TA. Fetal dexamethasone exposure affects basal ornithine decarboxylase activity in developing rat brain regions and alters acute responses to hypoxia and maternal separation. Biol Neonate 59:69-77 (1991).
30. Jonsson G, Hallman H. Effects of neonatal nicotine administration on the postnatal development of central noradrenaline neurons. Acta Physiol Scand Suppl 479:25-261 (1980).
31. Slotkin TA. Prenatal exposure to nicotine: What can we learn from animal models? In: Maternal Substance Abuse and the Developing Nervous System (Zagon IS, Slotkin TA, eds). San Diego: Academic Press, 1992:97-124.
32. Slotkin TA, Orband-Miller L, Queen KL, Whitmor WL, Seidler FJ. Effects of prenatal nicotine exposure on biochemical development of rat brain regions: maternal drug infusions via osmotic minipumps. J Pharmacol Exp Ther 240: 602-611 (1987).
33. Navarro HA, Seidler FJ, Whitmore WL, Slotkin TA. Prenatal exposure to nicotine via maternal infusions: effects on development of catecholamine systems. J Pharmacol Exp Ther 244:940-944 (1988).
34. Navarro HA, Seidler FJ, Schwart RD, Baker,FE, Dobbins SS, Slotkin TA. Prenatal exposure to nicotine impairs nervous system development at a dose which does not affect viability or growth. Brain Res Bull 23:187-192 (1989).
35. Murrin LC, Ferrer JR, Wanyun Z, Haley NJ. Nicotine administration to rats: methodological considerations. Life Sci 40:1699-1708 (1987).
36. Lichtensteiger W, Ribary U, Schlumpf M, Odermatt B, Widmer HR. Prenatal adverse effects of nicotine on the developing brain. Prog Brain Res 73:137-157 (1988).
37. Barnes CD, Eltherington LG. Drug Dosage in Laboratory Animals: A Handbook. Revised ed. Berkeley, CA:University of California Press, 1973.
38. Slotkin TA, McCook EC, Seidler FJ. Cryptic brain cell injury caused by fetal nicotine exposure is associated with persistent elevations of c-fos protooncogene expression. Brain Res 750:180-188 (1997).
39. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther 285:931-945 (1998).
40. Roy TS, Andrews JE, Seidler FJ, Slotkin TA. Nicotine evokes cell death in embryonic rat brain during neurulation. J Pharmacol Exp Ther (in press).
41. Owman C, Fuxe K, Janson AM, Kahrstrom J. Chronic nicotine treatment eliminates asymmetry in striatal glucose utilization following unilateral transection of the mesostriatal dopamine pathway in rats. Neurosci Lett 102:279-283 (1989).
42. Janson AM, Fuxe K, Agnati LF, Kitayama I, Harfstrand A, Andersson K, Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunore-active nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res 455:332-345 (1988).
43. Yamashita H, Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neurosci Lett 213:145-147 (1996).
44. Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via α7-neuronal receptors and neuronal CNS receptors. Brain Res 765:135-140 (1997).
45. Curran T, Abate C, Cohen DR, Macgregor PF, Rauscher FJ, Sonnenberg JL, Connor JA, Morgan, JI. Inducible proto-oncogene transcription factors: third messengers in the brain? Cold Spring Harbor Symp Quant Biol 55:225-234 (1990).
46. Curran T, Morgan JI. Fos: an immediate-early transcription factor in neurons. J Neurobiol 26:403-412 (1995).
47. Scotting, PJ, Rex, M. Transcription factors in early development of the central nervous system. Neuropathol Appl Neurobiol 22:469-481 (1996).
48. Blishchenko EY, Mirkina II, Mernenko OA, Yatskin ON, Satpaev DK, Strizhkov BN, Karelin AA. Cytotoxic activity of acetylcholine receptor ligands. Biochem Mol Biol Int 42:739-747 (1997).
49. 3H]hemi-cholinium-3 binding. Neurotoxicol Teratol 14:375-382 (1992).
50. Lichtensteiger W, Schlumpf M. Prenatal nicotine affects fetal testosterone and sexual dimorphism of saccharin preference. Pharmacol Biochem Behav 23:439-144 (1985).
51. Ribary U, Lichtensteiger W. Effects of acute and chronic prenatal nicotine treatment on central catecholamine systems of male and female rat fetuses and offspring. J Pharmacol Exp Ther 248:786-792 (1989).
52. Seidler FJ, Levin ED, Lappi SE, Slotkin TA. Fetal nicotine exposure ablates the ability of postnatal nicotine challenge to release norepinephrine from rat brain regions. Dev Brain Res 69:288-291 (1992).
53. Slotkin TA, Navarro HA, McCook EC, Seidler FJ. Fetal nicotine exposure produces postnatal upregulation of adenylate cyclase activity in peripheral tissues. Life Sci 47:1561-1567 (1990).
54. Slotkin TA, McCook EC, Lappi SE, Seidler FJ. Altered development of basal and forskolin-stimulated adenylate cyclase activity in brain regions of rats exposed to nicotine prenatally. Dev Brain Res 68:233-239 (1992).
55. 1-receptors and their link to G-proteins. Neurotoxicol Teratol 15:107-115 (1993).
56. Navarro HA, Mills E, Seidler FJ, Baker FE, Lappi SE, Tayyeb MI, Spencer JR, Slotkin TA. Prenatal nicotine exposure impairs β-adrenergic function: persistent chronotropic subsensitivity despite recovery from deficits in receptor binding. Brain Res Bull 25:233-237 (1990).
57. 1-receptors. Res Commun Subst Abuse 11:95-103 (1990).
58. Dodge PR, Prensky AL, Feigin RD. Nutrition and the Developing Nervous System. St. Louis:C.V. Mosby, 1975.
59. de Grauw TJ, Myers RE, Scott WJ. Fetal growth retardation in rats from different levels of hypoxia. Biol Neonate 49:85-89 (1986).
60. Bell JM, Whitmore WL, Queen KL, Orband-Miller L, Slotkin TA. Biochemical determinants of growth sparing during neonatal nutritional deprivation or enhancement: ornithine decarboxylase, polyamines, and macromolecules in brain regions and heart. Pediatr Res 22:599-604 (1387).
61. 3H](-)nicotine label the same recognition site in rat brain. Mol Pharmacol 31:169-174 (1987).
62. 3H](-)Nicotine binding sites in fetal human brain. Brain Res 475:1-7 (1988).
63. 3H]nicotine binding in the fetal brain. Int. J Dev Neurosci 3:567-571 (1985).
64. 3H]nicotine binding in developing mouse brain, Int J Dev Neurosci 3:667-671 (1985).
65. Lichtensteiger W, Schlumpf M. Ribary U. Modifications pharmacologiques de l'ontogenèse neuroendocrine. Ann Endocrinol 48:393-399 (1987).
66. Smith WT, Seidler FJ, Slotkin TA. Acute stimulation of ornithine decarboxylase in neonatal rat brain regions by nicotine: a receptor-mediated process? Dev Brain Res 63:85-93 (1991).
67. Roy TS, Andrews JE, Seidler FJ, Slotkin TA. Chlorpyrifos elicits mitotic abnormalities and apoptosis in neuroepithelium of cultured rat embryos. Teratology 58:62-68 (1998).
68. Cutler AR, Wilkerson AE, Gingras JL, Levin ED. Prenatal cocaine and/or nicotine exposure in rats: preliminary findings on long-term cognitive outcome and genital development at birth. Neurotoxicol Teratol 18:635-643 (1996).
69. Levin ED, Wilkerson A, Jones JP, Christopher NC, Briggs SJ. Prenatal nicotine effects on memory in rats: pharmacological and behavioral challenges. Dev Brain Res 97:207-215 (1996).
70. Levin ED, Briggs SJ, Christopher NC, Rose JE. Prenatal nicotine exposure and cognitive performance in rats. Neurotoxicol Teratol 15:251-260 (1993).
71. Pugh PC, Berg DK. Neuronal acetylcholine receptors that bind α-garotoxin mediate neurite retraction in a calcium-dependent manner. J Neurosci 14:889-896 (1994).
72. Hellstrom-Lindahl E, Gorbounova O, Seiger A, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Dev Brain Res 108:147-160 (1998).
73. 2 mRNA species in the rat. Dev Brain Res 109:67-75 (1998).
74. Richardson RJ, Moore TB, Kayyali US, Randall JC. Chlorpyrifos: assessment of potential for delayed neurotoxicity by repeated dosing in adult hens with monitoring of brain acetylcholinesterase, brain and lymphocyte neurotoxic esterase and plasma butyrylcholinesterase activities. Fundam Appl Toxicol 21:89-96 (1993).
75. Fenske RA, Black KG, Elkner KP, Lee C, Methner MM, Soto R. Potential exposure and health risks of infants following indoor residential pesticide applications. Am J Public Health 80:689-693 (1990).
76. Gurunathan S, Robson M, Freeman N, Buckley B, Roy A, Meyer R, Bukowski J, Lioy PJ. Accumulation of chlorpyrifos on residential surfaces and toys accessible to children. Environ Health Perspect 106:9-16 (1998).
77. Whitney KD, Seidler FJ, Slotkin TA. Developmental neurotoxicity of chlorpyrifos: cellular mechanisms. Toxicol Appl Pharmacol 134:53-62 (1995).
78. Pope CN, Chakraborti TK, Chapman ML, Farrar JD, Arthun D. Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides. Toxicology 68:51-61 (1991).
79. Pope CN, Chakraborti TK. Dose-related inhibition of brain and plasma cholinesterase in neonatal and adult rats following sublethal organophosphate exposures. Toxicology 73:35-43 (1992).
80. Song X, Seidler FJ, Saleh JL, Zhang J, Padilla S. Slotkin TA. Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Toxicol Appl Pharmacol 145:158-174 (1997).
81. Katz EJ, Cortes VI, Eldefrawi ME, Eldefrawi AT. Chlorpyrifos, parathion, and their oxons bind to and desensitize a nicotinic acetylcholine receptor: relevance to their toxicities. Toxicol Appl Pharmacol 146:227-236 (1997).
82. Huff RA, Abou-Donia MB. In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. Neurotoxicology 16:281-290 (1995).
83. Huff RA, Corcoran JJ, Anderson JK, Abou-Donia MB. Chlorpyrifos oxon binds directly to muscarinic receptors and inhibits cAMP accumulation in rat striatum. J Pharmacol Exp Ther 269:329-335 (1994).
84. Bagchi D, Bagchi M, Hassoun EA, Stohs SJ. In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology 104:129-140 (1995).
85. Bagchi D, Bhattacharya G, Stohs SJ. In vitro and in vivo induction of heat shock (stress) protein (Hsp) gene expression by selected pesticides. Toxicology 112:57-68 (1996).
86. Dam K, Seidler FJ, Slotkin TA. Developmental neurotoxicity of chlorpyrifos: delayed targeting of DNA synthesis after repeated administration. Dev Brain Res 108:39-45 (1998).
87. Campbell CG, Seidler FJ, Slotkin TA. Chlorpyrifos interferes with cell development in rat brain regions. Brain Res Bull 43:179-189 (1997).
88. Johnson DE, Seidler FJ, Slotkin TA. Early biochemical detection of delayed neurotoxicity resulting from developmental exposure to chlorpyrifos. Brain Res Bull 45:143-147 (1998).
89. Ward TR, Mundy WR. Organophosphorus compounds preferentially affect second messenger systems coupled to M2/M4 receptors in rat frontal cortex. Brain Res Bull 39:49-55 (1996).
90. Claycomb WC. Biochemical aspects of cardiac muscle differentiation. J Biol Chem 251: 6082-6089 (1976).
91. Hultgårdh-Nilsson A, Querol-Ferrer V, Jonzon B, Krondahl, U, Nilsson J. Cyclic AMP, early response gene expression, and DNA synthesis in rat smooth muscle cells. Exp Cell Res 214:297-302 (1994).
92. Van Wijk R, Wicks WD, Bevers MM, Van Rijn J. Rapid arrest of DNA synthesis by N6,02'-dibutyryl cyclic adenosine 3′,5′-monophosphate in cultured hepatoma cells. Cancer Res 33: 1331-1338 (1973).
93. Bhat NR, Shanker G, Pieringer RA. Cell proliferation in growing cultures of dissociated embryonic mouse brain: macromolecule and ornithine decarboxylase synthesis and regulation by hormones and drugs. J Neurosci Res 10:221-230 (1983).
94. Guidotti A. Adenosine 3′,5′-monophosphate concentrations and isoproterenol-induced synthesis of deoxyribonucleic acid in mouse parotid gland. Mol Pharmacol 8:521-530 (1972).
95. Tischler AS, Greene LA. Nerve growth factor-induced process formation by cultured rat pheochromocytoma cells. Nature 253:341-342 (1975).
96. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci 73: 2424-2428 (1976).
97. Greene LA, Rukenstein A. Regulation of acetylcholinesterase activity by nerve growth factor: role of transcription and dissociation from effects on proliferation and neurite outgrowth. J Biol Chem 256:6363-6367 (1981).
98. Berse B, Blusztajn JK. Modulation of cholinergic locus expression by glucocorticoids and retinoic acid is cell-type specific. FEBS Lett 410:175-179 (1997).
99. Mapoles J, Berthou F, Alexander A. Simon F, Menez JF. Mammalian PC-12 cell genetically engineered for human cytochrome P450 2E1 expression. J Biochem 214:735-745 (1993).
100. Song X, Violin JD, Seidler FJ, Slotkin TA. Modeling the developmental neurotoxicity of chlorpyrifos in vitro, macromolecule synthesis in PC12 cells. Toxicol Appl Pharmacol 151: 182-191 (1998).
101. Muscarella DE, Keown JF, Bloom SE. Evaluation of the genotoxic and embryotoxic potential of chlorpyrifos and its metabolites in vivo and in vitro. Environ Mutagen 6:13-23 (1984).
102. Cosenza ME, Bidanet J. Effects of chlorpyrifos on neuronal development in rat embryo midbrain micromass cultures. Vet Human Toxicol 37:118-121 (1995).
103. Hunter DL, Lassiter TL, Chanda SM, Barone S, Padilla S. Pharmacokinetics of chlorpyrifos and its metabolites in maternal and fetal brain and liver tissue following gestational exposure. Toxicologist42:157-158 (1998).
104. Chakraborti TK, Farrar JD, Pope CN. Comparative neurochemical and neurobehavioral effects of repeated chlorpyrifos exposures in young and adult rats. Pharmacol Biochem Behav 46:219-224 (1993).
105. Bushnell PJ, Pope CN, Padilla S. Behavioral and neurochemical effects of acute chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase. J Pharmacol Exp Ther 266:1007-1017 (1993).
106. Tolson CM, Seidler FJ, McCook EC, Slotkin TA. Does concurrent or prior nicotine exposure interact with neonatal hypoxia to produce cardiac cell damage? Teratology 52:298-305 (1995).